DK3389717T3 - Neoadjuvansterapi for blærekræft - Google Patents
Neoadjuvansterapi for blærekræft Download PDFInfo
- Publication number
- DK3389717T3 DK3389717T3 DK16819894.3T DK16819894T DK3389717T3 DK 3389717 T3 DK3389717 T3 DK 3389717T3 DK 16819894 T DK16819894 T DK 16819894T DK 3389717 T3 DK3389717 T3 DK 3389717T3
- Authority
- DK
- Denmark
- Prior art keywords
- bladder cancer
- neoadjuvant therapy
- neoadjuvant
- therapy
- bladder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
- A61N2005/061—Bladder and/or urethra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0626—Monitoring, verifying, controlling systems and methods
- A61N2005/0629—Sequential activation of light sources
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
- A61N2005/0663—Coloured light
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1522309.2A GB201522309D0 (en) | 2015-12-17 | 2015-12-17 | Use |
| PCT/EP2016/081803 WO2017103283A1 (en) | 2015-12-17 | 2016-12-19 | Neoadjuvant therapy for bladder cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3389717T3 true DK3389717T3 (da) | 2025-03-31 |
Family
ID=55311159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16819894.3T DK3389717T3 (da) | 2015-12-17 | 2016-12-19 | Neoadjuvansterapi for blærekræft |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10556010B2 (https=) |
| EP (1) | EP3389717B9 (https=) |
| JP (1) | JP6926086B2 (https=) |
| KR (1) | KR102787188B1 (https=) |
| CN (2) | CN108601836A (https=) |
| AU (1) | AU2016372573B2 (https=) |
| BR (1) | BR112018012009B1 (https=) |
| DK (1) | DK3389717T3 (https=) |
| ES (1) | ES3015668T3 (https=) |
| FI (1) | FI3389717T3 (https=) |
| GB (1) | GB201522309D0 (https=) |
| PL (1) | PL3389717T3 (https=) |
| WO (1) | WO2017103283A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201522311D0 (en) * | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| GB201522309D0 (en) * | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| US11266619B2 (en) * | 2017-12-01 | 2022-03-08 | Sbi Pharmaceuticals Co., Ltd. | Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor |
| KR102441358B1 (ko) | 2020-09-14 | 2022-09-06 | 주식회사 아파트엔 | 아파트의 지수화를 통한 아파트 투자 가치 평가 시스템 |
| CN120957714A (zh) | 2023-03-07 | 2025-11-14 | 光治疗Asa公司 | 膀胱癌疗法 |
| WO2026052815A1 (en) | 2024-09-05 | 2026-03-12 | Photocure Asa | Use of hal in a method for predicting bladder cancer immunotherapy response |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE202076T1 (de) | 1995-03-10 | 2001-06-15 | Photocure Asa | Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie |
| US7530461B2 (en) * | 1995-03-10 | 2009-05-12 | Photocure Asa | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
| GB0018528D0 (en) * | 2000-07-27 | 2000-09-13 | Photocure Asa | Compounds |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| GB0406917D0 (en) | 2004-03-26 | 2004-04-28 | Photocure Asa | Compounds |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| RU2526803C2 (ru) | 2009-06-11 | 2014-08-27 | ФотоКьюэр АСА | Полутвердые композиции и фармацевтические продукты |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| WO2013181452A1 (en) | 2012-05-31 | 2013-12-05 | Genentech, Inc. | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
| US8927761B2 (en) | 2012-06-28 | 2015-01-06 | Photocure Asa | Form of hexyl-5-aminolevulinate hydrochloride and methods of using the same |
| CA2880422C (en) * | 2012-08-03 | 2021-02-09 | Photocure Asa | Derivatives of 5-aminolevulinic acid |
| GB201522309D0 (en) * | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| CN109010850B (zh) * | 2018-08-01 | 2021-10-22 | 上海师范大学 | 一种负载姜黄素的葡聚糖修饰的钆掺杂的空心介孔二氧化硅纳米材料的制备方法及应用 |
-
2015
- 2015-12-17 GB GBGB1522309.2A patent/GB201522309D0/en not_active Ceased
-
2016
- 2016-12-19 BR BR112018012009-0A patent/BR112018012009B1/pt active IP Right Grant
- 2016-12-19 US US16/063,185 patent/US10556010B2/en active Active
- 2016-12-19 CN CN201680079674.2A patent/CN108601836A/zh active Pending
- 2016-12-19 KR KR1020187020006A patent/KR102787188B1/ko active Active
- 2016-12-19 AU AU2016372573A patent/AU2016372573B2/en active Active
- 2016-12-19 FI FIEP16819894.3T patent/FI3389717T3/fi active
- 2016-12-19 ES ES16819894T patent/ES3015668T3/es active Active
- 2016-12-19 EP EP16819894.3A patent/EP3389717B9/en active Active
- 2016-12-19 JP JP2018531667A patent/JP6926086B2/ja active Active
- 2016-12-19 DK DK16819894.3T patent/DK3389717T3/da active
- 2016-12-19 WO PCT/EP2016/081803 patent/WO2017103283A1/en not_active Ceased
- 2016-12-19 CN CN202411498667.9A patent/CN119345359A/zh active Pending
- 2016-12-19 PL PL16819894.3T patent/PL3389717T3/pl unknown
-
2020
- 2020-01-21 US US16/748,332 patent/US11311620B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018124868A3 (https=) | 2020-05-13 |
| KR20180094987A (ko) | 2018-08-24 |
| US20180369379A1 (en) | 2018-12-27 |
| JP2018537514A (ja) | 2018-12-20 |
| WO2017103283A1 (en) | 2017-06-22 |
| AU2016372573B2 (en) | 2022-07-21 |
| EP3389717A1 (en) | 2018-10-24 |
| GB201522309D0 (en) | 2016-02-03 |
| CA3008551A1 (en) | 2017-06-22 |
| CN119345359A (zh) | 2025-01-24 |
| EP3389717B1 (en) | 2025-02-19 |
| FI3389717T3 (fi) | 2025-04-08 |
| US20200155683A1 (en) | 2020-05-21 |
| BR112018012009A2 (pt) | 2018-12-04 |
| CN108601836A (zh) | 2018-09-28 |
| US11311620B2 (en) | 2022-04-26 |
| EP3389717B9 (en) | 2025-07-23 |
| AU2016372573A1 (en) | 2018-07-12 |
| BR112018012009B1 (pt) | 2023-12-19 |
| KR102787188B1 (ko) | 2025-03-25 |
| ES3015668T3 (en) | 2025-05-07 |
| US10556010B2 (en) | 2020-02-11 |
| PL3389717T3 (pl) | 2025-06-09 |
| JP6926086B2 (ja) | 2021-08-25 |
| RU2018124868A (ru) | 2020-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL261468A (en) | Uterine cancer treatments | |
| IL255261A0 (en) | Methods for treating cancer | |
| HUE053903T2 (hu) | Kombinációs terápia rák ellen | |
| IL255312A0 (en) | Therapeutic and diagnostic methods for cancer | |
| IL252796B (en) | Therapeutic, diagnostic and prognostic methods for cancer of the bladder | |
| EP3463464A4 (en) | ASSOCIATION TREATMENT | |
| HUE054012T2 (hu) | Kombinációs terápia rák ellen | |
| IL258684A (en) | Combination therapy for treating malignancies | |
| PT3197456T (pt) | Tratamentos de cancro | |
| KR20180084772A (ko) | 암 치료를 위한 조합 치료법 | |
| IL284875A (en) | Lasofoxifene treatment of breast cancer | |
| PL3458052T3 (pl) | Leczenie skojarzone nowotworu | |
| EP3413927A4 (en) | CANCER THERAPY | |
| EP3546020C0 (en) | CANCER TREATMENT DEVICE | |
| DK3768830T5 (da) | Cancerterapi | |
| EP3593139C0 (en) | CANCER BIOMARKERS | |
| DK3576740T3 (da) | Cancerbehandling | |
| HUE040167T2 (hu) | Rákkezelés | |
| EP3576791A4 (en) | CALRETICULIN-MEDIATION CANCER TREATMENT | |
| HUE056897T2 (hu) | Monomaleimid-funkcionalizált platinavegyületek rákterápiához | |
| DK3393478T3 (da) | Kombinationsterapi | |
| EP3362091A4 (en) | COMBINATION THERAPY | |
| DK3389717T3 (da) | Neoadjuvansterapi for blærekræft | |
| DK3383385T3 (da) | Melflufen-doseringsregimer for cancer | |
| DK3407909T5 (da) | Cancerbehandling |